Clinical Trial

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy participants
Protocol Amendment History 2 changes
critical Trial completed 2026-06-27
minor Completion moved earlier: 2026-12-31 -> 2026-04-20 2026-06-27
Trial Details
NCT Number NCT07198087
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Primary Central Nervous System Lymphoma (PCNSL)
Enrollment 40 participants
Start Date 2025-10-01
Primary Completion 2026-04-09 (estimated)
Study Completion 2026-04-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-26